BioVie Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Cuong Viet Do
- Full Time Employees
- 14
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 680 West Nye Lane Carson City NV United States of America 89703
- IPO Date
- Sep 18, 2020
- CIK
- 0001580149
- Website
- bioviepharma.com
- Similar Companies
- Business
- BioVie Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative drug therapies for neurological and neurodegenerative disorders, including Alzheimer's disease, Parkinson’s disease, and long COVID, as well as advanced liver disease. The company's core products include bezisterim, a novel oral small molecule that inhibits tumor necrosis factor alpha (TNF-α) to reduce neuroinflammation and insulin resistance, currently in clinical trials for Alzheimer's, Parkinson’s, and neurological symptoms of long COVID. In liver disease, BioVie develops BIV201 (continuous infusion terlipressin), an orphan drug candidate with FDA Fast Track designation aimed at reducing further decompensation in patients with liver cirrhosis and ascites; this active agent is already approved in the U.S. and about 40 other countries for related complications of advanced liver cirrhosis. BioVie pursues therapeutic areas involving neuroinflammation, energy metabolism in the brain, and advanced liver cirrhosis complications with significant unmet medical needs. The company was incorporated in 2013 and is headquartered in Carson City, Nevada. It underwent a name change from NanoAntibiotics, Inc. to BioVie Inc. in July 2016. BioVie operates primarily in the biotechnology and pharmaceuticals sectors, focusing on clinical-stage drug development with an emphasis on severe chronic conditions affecting neurology and liver disease markets globally. Recent major developments include the closing of a $12 million public offering in August 2025 to support ongoing clinical development programs. The company is actively engaging in partnerships to advance its Phase 3 trial design for BIV201 targeting refractory ascites patients, reflecting a strategic expansion into late-stage liver disease therapeutics. Additionally, BioVie partnered with New to The Street, a media production company, for an extensive media campaign to raise corporate and investor awareness. The company continues to prioritize its innovative pipeline, including advancing the Phase 3 trial of NE3107 for mild to moderate Alzheimer’s disease, while expanding clinical efforts in Parkinson’s disease and long COVID neurological symptoms. BioVie addresses large underserved markets characterized by high unmet clinical needs and mortality rates, with its pipeline drugs focused on novel mechanisms like inflammation and insulin resistance modulation for neurodegenerative diseases and complications of liver cirrhosis. This strategic focus distinguishes it in the competitive biopharmaceutical landscape and positions it for potential regulatory approvals and market entry in the near term. The company's comprehensive drug development portfolio and recent funding and partnership activities underscore its commitment to progressing its clinical candidates toward commercialization. BioVie’s headquarters is located at 680 W. Nye Lane, Suite 204, Carson City, Nevada, USA. The company remains a Nasdaq-listed entity under the ticker symbol BIVI. Its therapeutic advances and clinical-stage status make it a significant player in biotechnology with a growing focus on neurological and liver disease treatment innovations. This description is based on the latest publicly available information as of December 2025.
BioVie Inc. (BIVI) Discusses Clinical Updates on Bezisterim and BIV201 for Parkinson's, Alzheimer's, and Ascites Transcript
BioVie: Long COVID trial fully enrolled – ICYMI
BioVie: Long COVID trial fully enrolled – ICYMI
Join BioVie's Exclusive Live Investor Webinar and Q and A Session on June 2
BioVie to highlight neuro and liver disease programs in June 2 investor webinar
BioVie completes enrollment in Phase 2 Long COVID trial
BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
BioVie completes final patient visit in Parkinson's drug trial
BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson's Disease
BioVie Inc. (BIVI) Discusses Bezisterim's Mechanism of Action and Its Potential in Addressing Parkinson's Disease Pathology Transcript
BioVie CEO shares insights into long COVID trial - ICYMI
BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026
BioVie abstract on Parkinson's drug accepted for neurology conference
BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting
United, American Airlines possible merger discussed at White House meeting: report
Conagra Brands shares slide as CEO Connolly ousted
Deutsche Bank cuts RS Group to hold as industrial recovery outlook clouds
Shell and BP shares lifted as oil rebounds on breakdown of US-Iran peace talks
BioVie CEO explains Bezisterim Parkinson's trial results - ICYMI
BioVie CEO explains Bezisterim Parkinson’s trial results - ICYMI